- Home
- HTGC vs RARE Comparison
HTGC vs RARE Comparison
Compare HTGC & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTGC | RARE |
|---|---|---|
| Founded | 2003 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.2B |
| IPO Year | 2005 | 2014 |
Fundamental Metrics
Financial Performance| Metric | HTGC | RARE |
|---|---|---|
| Price | $18.94 | $36.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 15 |
| Target Price | $21.13 | ★ $85.20 |
| AVG Volume (30 Days) | 1.3M | ★ 1.3M |
| Earning Date | 10-30-2025 | 11-04-2025 |
| Dividend Yield | ★ 9.94% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.75 | N/A |
| Revenue | $516,847,000.00 | ★ $630,598,000.00 |
| Revenue This Year | $8.72 | $19.09 |
| Revenue Next Year | $9.57 | $20.62 |
| P/E Ratio | $10.80 | ★ N/A |
| Revenue Growth | 4.54 | ★ 20.63 |
| 52 Week Low | $15.65 | $25.81 |
| 52 Week High | $22.04 | $50.00 |
Technical Indicators
Market Signals| Indicator | HTGC | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 69.30 | 62.96 |
| Support Level | $17.86 | $35.94 |
| Resistance Level | $19.13 | $39.89 |
| Average True Range (ATR) | 0.27 | 1.68 |
| MACD | 0.16 | 0.35 |
| Stochastic Oscillator | 89.45 | 60.91 |
Price Performance
Historical ComparisonAbout HTGC Hercules Capital Inc.
Hercules Capital Inc is a specialty finance company that provides senior secured loans to high-growth, venture capital-backed companies in various technology, life sciences, and sustainable and renewable technology industries. It invests majorly in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The company lends to and invests in portfolio companies in various technology-related industries, including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.